Research programme: small molecule neurogenic therapeutics - Palisade Bio
Alternative Names: NSI-144; NSI-150; NSI-158Latest Information Update: 29 Apr 2021
At a glance
- Originator Neuralstem
- Developer Seneca Biopharma
- Class Small molecules
- Mechanism of Action Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 27 Apr 2021 Leading BioSciences has merged with Seneca Biopharma to form Palisade Bio
- 28 Oct 2019 Neuralstem is now called Seneca Biopharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA (PO)